Genetic Testing

The genetic testing market is growing rapidly, with more than 175,000 tests available today. Our Genetic Testing Management solution addresses the significant complexity that exists in genetic testing by ensuring that medical necessity criteria has been met for tests that may frequently be used inappropriately.

Genetic Testing Clinical Guidelines for January 1, 2026 Implementation:

• Autism Spectrum Disorder/Intellectual Disability Panel Analysis
• Bladder Cancer Treatment and Recurrence Algorithmic Tests
• Breast Cancer Extended Endocrine Therapy Algorithmic Tests
• Breast Cancer Prognostic Algorithmic Tests
• Breast Cancer Treatment and Prognostic Algorithmic Tests
• Breast DCIS Prognostic Algorithmic Tests
• Broad Molecular Profiling Panel Tests via Circulating Tumor DNA_ctDNA
• Broad Molecular Profiling Panels For Hematologic Malignancies and Myeloid Malignancy Panels
• Chromosomal Microarray Analysis_CMA_for Pregnancy Loss
• Chromosomal Microarray Analysis_CMA_for Prenatal Diagnosis
• CM Analysis for Dev Delay_Intellectual Disability, Autism Spectrum DO, or Congenital Anomalies
• Colorectal Cancer Prognostic Algorithmic Tests
• Comprehensive Connective Tissue Disorders Multigene Panel
• Cutaneous Melanoma Diagnostic Algorithmic Tests
• Cutaneous Melanoma Prognostic Algorithmic Tests_
• Cutaneous Melanoma Risk Assessment Algorithmic Tests
• Donor-Derived Cell-free DNA for Heart Transplant Rejection
• Epilepsy Multigene Panel
• Evidence-Based Donor-Derived Cell-free for Solid Organ Transplant Rejection
• Evidence-Based Lung Cancer Risk Assessment Algorithmic Tests
• Evidence-Based Lung Cancer Treatment Algorithmic Tests
• Evidence-Based Prostate Cancer Risk Assessment and Diagnostic Algorithmic Tests
• Evidence-Based Solid Tumor Minimal Residual Disease_MRD_Testing
• Hereditary Breast and/or Ovarian Cancer Susceptibility Panels
• Hereditary Dystonia Multigene Panel
• Hereditary Gastrointestinal Colorectal Cancer Susceptibility Panels
• Hereditary Polyposis Susceptibility Panels
• HLA-DQ Genotyping Analysis
• Inflammatory Bowel Disease_Crohn’s Disease Diagnostic Algorithmic Tests
• Lung Cancer Focused Molecular Profiling Panels
• Lung Cancer Focused Panel Tests via Circulating Tumor DNA_ctDNA
• Mitochondrial Genome Sequencing, Deletion_Duplication, and_or Nuclear Gene Panel
• MLH1, MSH2, MSH6, PMS2, and_or EPCAM Sequencing and_or Deletion_Duplication Analysis
• Monogenic Diabetes_Including Maturity Onset Diabetes of the Young _MODY_Panels
• Noonan Spectrum Disorders_RASopathies Multigene Panel
• Ovarian Cancer Treatment Algorithmic Tests
• Pan-Cancer Hereditary Cancer Susceptibility Panels
• Pharmacogenetic Panel Tests
• Post Heart Transplant Gene Expression Panels for Rejection Risk via Peripheral Blood
• Prenatal Cell-free DNA Testing for Fetal RhD Genotyping
• Prostate Cancer Treatment and Prognostic Algorithmic Tests
• Rapid Exome Sequencing
• Rapid Genome Sequencing
• Reanalysis of Exome or Genome Sequencing Data
• Standard Exome Sequencing
• Standard Genome Sequencing
• Thyroid Cancer Diagnostic Algorithmic Tests
• Tumor Specific BCR-ABL1 FISH, Qualitative, and Quantitative Tests
• Tumor-Type Agnostic Solid Tumor Molecular Profiling Panels
• Uveal Melanoma Prognostic Algorithmic Tests